How Does Skyrizi (Risankizumab) Work? Mechanism of Action Explained in Plain English

Skyrizi (risankizumab-rzaa) is a biologic medication that targets a specific protein in the immune system called interleukin-23 (IL-23). Understanding how Skyrizi works helps explain why it is so effective for conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis — and why its side effect profile is generally more favorable than older biologics.

What Is IL-23, and Why Does It Matter?

Your immune system uses chemical messengers called cytokines to coordinate its response to threats like infections, injuries, and foreign substances. Interleukin-23 (IL-23) is one of these cytokines — a protein that plays a master-regulator role in driving chronic inflammation.

In healthy people, IL-23 helps the immune system respond to bacterial and fungal infections. But in people with autoimmune conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, IL-23 activity is excessive — the immune system turns on the body's own tissues and triggers the inflammation that causes disease symptoms.

The IL-23 Inflammatory Cascade: Step by Step

Here's how IL-23 drives disease in conditions like psoriasis:

Dendritic cells and macrophages in the skin or gut produce IL-23 in response to perceived threats.

IL-23 binds to receptors on Th17 immune cells, activating and expanding them.

Activated Th17 cells release more inflammatory cytokines (especially IL-17), which cause the symptoms of psoriasis (skin plaques), psoriatic arthritis (joint inflammation), and IBD (gut inflammation).

This inflammatory cycle becomes self-perpetuating without treatment.

How Skyrizi Breaks the Inflammatory Cycle

Skyrizi (risankizumab-rzaa) is a humanized monoclonal antibody — a laboratory-engineered protein that acts like a precision tool. It selectively binds to the p19 subunit of IL-23, physically blocking IL-23 from connecting with its receptor on immune cells.

By interrupting IL-23 signaling at this upstream point, Skyrizi suppresses the entire downstream inflammatory cascade. Th17 cells are not activated, IL-17 production drops, and inflammation in the skin, joints, and gut decreases — leading to symptom relief.

Why Skyrizi Is More Targeted Than Older Biologics

IL-23 is a heterodimer — a protein made of two subunits called p19 and p40. Skyrizi specifically targets only the p19 subunit of IL-23. This selective targeting is important because:

Older IL-12/23 inhibitors like Stelara (ustekinumab) block both IL-12 and IL-23 by targeting the shared p40 subunit. This broader suppression may interfere with more immune pathways.

By targeting only p19 (unique to IL-23), Skyrizi leaves IL-12 pathways intact. IL-12 plays an important role in fighting certain infections and tumors — preserving it may contribute to Skyrizi's favorable safety profile.

Compared to IL-17 inhibitors like Cosentyx (secukinumab) or Taltz (ixekizumab), which block the end of the inflammatory pathway, Skyrizi acts earlier in the cascade — blocking the signal that triggers IL-17 production in the first place.

How Long Does It Take for Skyrizi to Work?

Most patients with plaque psoriasis begin to see improvement in skin clearance by week 8 to 16. In clinical trials (UltIMMa-1 and UltIMMa-2), 75% of patients achieved PASI 90 (90% reduction in psoriasis) by week 16, and about 58% achieved complete clear skin (PASI 100). Responses tend to be durable — many patients maintain high-level clearance for years.

For Crohn's disease and UC, the IV induction doses at weeks 0, 4, and 8 are designed to rapidly suppress inflammation, with clinical response often assessed at week 12 when maintenance SC dosing begins.

What Happens When You Stop Taking Skyrizi?

Skyrizi does not cure autoimmune conditions — it controls them. If you stop taking Skyrizi, the inflammatory signals resume, and symptoms typically return. Clinical trial data shows that patients who discontinued Skyrizi after achieving remission experienced a return of psoriasis, though many were able to recapture response when retreated.

For a full overview of Skyrizi's dosing and approved uses, see What Is Skyrizi? Uses, Dosage, and What You Need to Know. Once prescribed, medfinder can help you find a specialty pharmacy to fill your prescription.